Cat. No：GM-C13190
Product：Tango-H_CCR8 CHO-K1 Cell Line
Cat. No：GM-C13190
Product：Tango-H_CCR8 CHO-K1 Cell Line
Cell Growth Medium： F12K+10% FBS+1% P.S+4ug/ml Blasticidin+4ug/ml Puromycin+100ug/ml Hygromycin+200ug/ml G418
Cell Freezing Medium： FBS+10% DMSO
Assay Buffer： F12K+1% FBS+1% P.S
G protein-coupled receptors (GPCRs) are the largest membrane protein family in humans and represent important targets for many drugs. With over 800 members in the GPCR family, nearly 400 can be considered as potential drug targets. GPCR-targeting drugs account for 34% of all FDA-approved medications, primarily used for conditions like hypertension, diabetes, obesity, allergies, Alzheimer's disease, and various central nervous system disorders.
GPCR activation involves two signaling pathways: G protein-dependent and non-G protein-dependent pathways. In the G protein-dependent pathway, GPCRs couple with intracellular G proteins (Gi/Go, Gs, Gq, and G12/G13), leading to activation or inhibition of signals that can be detected through second messengers like calcium flux, cyclic adenosine monophosphate (cAMP), etc. The non-G protein-dependent pathway involves GPCR-induced β-arrestin translocation, independent of G protein receptor signaling, and can be utilized for orphan receptors, allowing the detection of non-G protein-dependent pathway activation.
CCR8 is the only known receptor for CCL1. CCL1 is secreted by tumor stromal cells and tumor-associated macrophages into the cancer microenvironment, where it activates the CCR8 receptor on cancer cells, promoting their proliferation, migration, and resistance to apoptosis. Additionally, it induces angiogenesis via the activation of CCR8 on endothelial cells. Another key function of CCL1 is recruiting regulatory T cells (Treg) to the tumor niche, leading to the conversion of CD4+ T cells into Tregs. CCR8 is specifically expressed on regulatory T cells infiltrating tumors but is barely expressed on peripheral blood Tregs or normal tissues, making it a promising target for cancer therapy.
The Tango-H_CCR8-CHO-K1 Cell Line utilizes CHO-K1 cells as host cells and integrates the Tango technology to construct a cell line with a Tango CCR8 reporter gene. Upon ligand activation of the CCR8 Arrestin pathway, Arrestin carries protein kinases that cut transcriptional activation elements, leading to their translocation to the cell nucleus and activating the luciferase reporter gene. The Luciferase reporter gene readout indicates the effectiveness of the signaling pathway activation, making it suitable for detecting the activity of functional antibodies targeting CCR8.
| CCL1:CCR8 | ||
| Cynomolgus_CCR8 CHO-K1 Cell Line | H_CCR8 CHO-K1 Cell Line | H_CCR8 HEK-293 Cell Line |
| H_CCR8 Jurkat Cell Line | H_CCR8 U2OS Cell Line | Mouse_CCR8 CHO-K1 Cell Line |
| Rhesus_CCR8-eGFP CHO-K1 Cell Line | ||
| Anti-Cynomolgus_CCR8 hIgG1 Antibody（TPP-21360） | Anti-H_CCR8 hIgG1 Antibody(Defucosylated,BMS-986340) | Anti-H_CCR8 hIgG1 Reference Antibody(BAY-3375968) |
| Anti-H_CCR8 hIgG1 Reference Antibody, Defucosylation (JTX-1811) | Anti-H_CCR8 mIgG1 Antibody(GS-1811) | Anti-H_CCR8 mIgG2a Reference Antibody (433H) |
| Anti-Mouse_CCR8 mIgG2a Antibody | ||
| Human CCR8-N1-35 Protein; hFc Tag | Human CCR8-N1-35 Protein; mFc Tag | |
Fan G, Yang H, Fong K C, et al. Methods and Compositions for Targeting Tregs using CCR8 Inhibitors: U.S. Patent Application 18/088,447[P]. 2023-5-25.
Wu Y, Xi J, Li Y, Li Z, Zhang Y, Wang J, Fan GH. Discovery of a Potent and Selective CCR8 Small Molecular Antagonist IPG7236 for the Treatment of Cancer. J Med Chem. 2023 Apr 13;66(7):4548-4564. doi: 10.1021/acs.jmedchem.3c00030. Epub 2023 Mar 29. PMID: 36988587.
Cat. No：GM-C13190
Product：Tango-H_CCR8 CHO-K1 Cell Line
Cell Growth Medium： F12K+10% FBS+1% P.S+4ug/ml Blasticidin+4ug/ml Puromycin+100ug/ml Hygromycin+200ug/ml G418
Cell Freezing Medium： FBS+10% DMSO
Assay Buffer： F12K+1% FBS+1% P.S
G protein-coupled receptors (GPCRs) are the largest membrane protein family in humans and represent important targets for many drugs. With over 800 members in the GPCR family, nearly 400 can be considered as potential drug targets. GPCR-targeting drugs account for 34% of all FDA-approved medications, primarily used for conditions like hypertension, diabetes, obesity, allergies, Alzheimer's disease, and various central nervous system disorders.
GPCR activation involves two signaling pathways: G protein-dependent and non-G protein-dependent pathways. In the G protein-dependent pathway, GPCRs couple with intracellular G proteins (Gi/Go, Gs, Gq, and G12/G13), leading to activation or inhibition of signals that can be detected through second messengers like calcium flux, cyclic adenosine monophosphate (cAMP), etc. The non-G protein-dependent pathway involves GPCR-induced β-arrestin translocation, independent of G protein receptor signaling, and can be utilized for orphan receptors, allowing the detection of non-G protein-dependent pathway activation.
CCR8 is the only known receptor for CCL1. CCL1 is secreted by tumor stromal cells and tumor-associated macrophages into the cancer microenvironment, where it activates the CCR8 receptor on cancer cells, promoting their proliferation, migration, and resistance to apoptosis. Additionally, it induces angiogenesis via the activation of CCR8 on endothelial cells. Another key function of CCL1 is recruiting regulatory T cells (Treg) to the tumor niche, leading to the conversion of CD4+ T cells into Tregs. CCR8 is specifically expressed on regulatory T cells infiltrating tumors but is barely expressed on peripheral blood Tregs or normal tissues, making it a promising target for cancer therapy.
The Tango-H_CCR8-CHO-K1 Cell Line utilizes CHO-K1 cells as host cells and integrates the Tango technology to construct a cell line with a Tango CCR8 reporter gene. Upon ligand activation of the CCR8 Arrestin pathway, Arrestin carries protein kinases that cut transcriptional activation elements, leading to their translocation to the cell nucleus and activating the luciferase reporter gene. The Luciferase reporter gene readout indicates the effectiveness of the signaling pathway activation, making it suitable for detecting the activity of functional antibodies targeting CCR8.
| CCL1:CCR8 | ||
| Cynomolgus_CCR8 CHO-K1 Cell Line | H_CCR8 CHO-K1 Cell Line | H_CCR8 HEK-293 Cell Line |
| H_CCR8 Jurkat Cell Line | H_CCR8 U2OS Cell Line | Mouse_CCR8 CHO-K1 Cell Line |
| Rhesus_CCR8-eGFP CHO-K1 Cell Line | ||
| Anti-Cynomolgus_CCR8 hIgG1 Antibody（TPP-21360） | Anti-H_CCR8 hIgG1 Antibody(Defucosylated,BMS-986340) | Anti-H_CCR8 hIgG1 Reference Antibody(BAY-3375968) |
| Anti-H_CCR8 hIgG1 Reference Antibody, Defucosylation (JTX-1811) | Anti-H_CCR8 mIgG1 Antibody(GS-1811) | Anti-H_CCR8 mIgG2a Reference Antibody (433H) |
| Anti-Mouse_CCR8 mIgG2a Antibody | ||
| Human CCR8-N1-35 Protein; hFc Tag | Human CCR8-N1-35 Protein; mFc Tag | |
Fan G, Yang H, Fong K C, et al. Methods and Compositions for Targeting Tregs using CCR8 Inhibitors: U.S. Patent Application 18/088,447[P]. 2023-5-25.
Wu Y, Xi J, Li Y, Li Z, Zhang Y, Wang J, Fan GH. Discovery of a Potent and Selective CCR8 Small Molecular Antagonist IPG7236 for the Treatment of Cancer. J Med Chem. 2023 Apr 13;66(7):4548-4564. doi: 10.1021/acs.jmedchem.3c00030. Epub 2023 Mar 29. PMID: 36988587.
